The next 12–18 months are shaping up to be unusually active for late-stage drug development as multiple high-profile candidates approach the end of pivotal trials or prepare for regulatory submission. A recent pipeline review from MMM Online notes that oncology, metabolic disease, and rare-disease therapies are driving the strongest momentum in late-stage development (source). Several programs are particularly closely watched:
- Eli Lilly’s Orforglipron, an oral non-peptide GLP-1 agonist, continues to advance toward late-stage regulatory discussions for obesity and metabolic disease, highlighted by BioPharma Dive’s clinical-watch analysis (analysis).
- Bluebird Bio’s lovo-cel for sickle cell disease and Rocket Pharma’s RP-L102 for Fanconi anemia were identified by Citeline as two gene-therapy candidates nearing the point of BLA submission in their Key Potential Drug Launches 2025 review (report).
- Alnylam’s vutrisiran, already approved for one form of hereditary transthyretin amyloidosis, is now approaching completion of expanded Phase III studies that could support a broader label, according to Prime Therapeutics’ Drug Pipeline (summary).
- Several oncology agents—including AstraZeneca’s datopotamab deruxtecan and Merck’s vibostolimab—have Phase III trials reaching final data collection in the coming year, with FDATracker’s 2025 clinical calendar noting imminent primary completion dates for multiple large studies (calendar).
Collectively, these programs point to one of the strongest near-term approval cohorts in years, particularly in gene therapy, metabolic disease, and immuno-oncology. As multiple sponsors prepare late-stage filings, the industry is poised for a significant wave of first-in-class and best-in-class therapies with meaningful clinical impact.
References
- MMM Online. Pipeline Report 2025: Late-Stage Programs Set to Reshape Treatment.
- Citeline. Key Potential Drug Launches in 2025.
- BioPharma Dive. Clinical Trials to Watch in 2025.
- Prime Therapeutics. Quarterly Drug Pipeline Report.
- ClinicalTrials.gov. Phase III Primary Completion Listings.